+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Nasal Polyps Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896210
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Intersect ENT Inc
  • Merck & Co Inc
  • Norton Waterford Ltd
  • Novartis International AG
  • MORE
Market Overview

The Nasal Polyps Treatment Market studied was anticipated to grow with a CAGR of nearly 6.2% during the forecast period. The major factors driving the growth of the market are the global prevalence of various cancers, immunological disorders, and the increasing geriatric population. For instance, the Centers for Disease Control and Prevention reports that in 2018, about 28.9 million adults in the United States were diagnosed with sinusitis which directly resulted in higher demand for the treatment fueling the growth of the market. Furthermore, an increase in the R&D investment in pharmaceuticals with a strong pipeline of products is expected to boost the growth of the global market throughout the forecasted period.

Scope of the Report

Nasal polyps are soft, painless, fleshy benign growths inside the paranasal sinuses and in the lining of the nose due to chronic inflammation of the mucosa. Generally, nasal polyps may occur due to asthma, allergic infections, sinus infections, cystic fibrosis, etc. The major symptoms associated with nasal polyps are nasal congestion, sinofacial pain, and loss of sense of smell.

Key Market Trends

The Corticosteroids Segment by Drug Class is Expected to Hold the Largest Market Share in the Nasal Polyps Treatment Market
  • The corticosteroid segment is expected to account for the largest market share in recent years and expected to do so over the forecast period. This dominance is due to an increase in the demand for corticosteroids treatment and its availability in various dosage forms like injections, intranasal sprays, and drops according to the need of the patient.
  • Also, the availability of various corticosteroids as topical formulations and aerosols which have the ability to decrease the size of nasal polyps, and thus heal the nasal polyps in patients has contributed to the significant share of revenue in the market. Furthermore, patient compliance for creams is more compared to other dosage forms available in the market.
  • The Hospital Pharmacies of distribution channel segment is expected to account for a significant share of the nasal polyps treatment market during the forecast period. Growth of the segment is expected to the availability of wide ranges of services by the advanced health care infrastructures at a single site along with the rise in the demand for surgical procedures for the removal of nasal polyps, resultant in increased hospitalization.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall nasal polyps treatment market throughout the forecast period. In the North America region, the united states are leading the market. This is mainly due to the Increased incidences of various cancers and allergic disorders such as asthma, sinusitis, and more, research activities in the United States coupled with increased approvals from regulatory bodies are likely to drive the growth of the nasal polyps treatment market. For instance, in June 2019, the U.S. Food & Drug Administration (FDA) approved Sanofi’s Dupixent, the first treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) which contributed for the largest share of revenue in the region.

Next to North America, Europe accounts for the Second-highest market revenue. This is due to factors such as the ongoing research and development activities, widespread adoption of advanced health care infrastructure that is fueling the huge product pipeline in the region.

The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the prevalence of allergic disorders and the steady growth of the pharmaceutical industry in recent years. China plays a pivotal role due in the Asia region to its high population and high extent of government initiatives to the healthcare sector. Ongoing trials in the region will further stimulate market growth in the region.

Competitive Landscape

The Nasal Polyps Treatment Market is moderately competitive and consists of several major players. Few of the major players are developing novel delivery systems to treat nasal polyps. which is expected to impel the global nasal polyps treatment market growth. For instance, in 2018, Intersect ENT Inc. launched SINUVA, a sinus implant containing mometasone furoate that is used to treat nasal polyps. Furthermore, few key players are entering into partnerships to develop and increase their market position globally. Some of the companies which are currently dominating the market are Sanofi S.A, OptiNose US, Merck & Co Inc, Intersect ENT Inc, and GlaxoSmithKline PLC

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Intersect ENT Inc
  • Merck & Co Inc
  • Norton Waterford Ltd
  • Novartis International AG
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of various Immunological Disorders along with the Increasing Geriatric Population
4.2.2 Huge Product Pipeline of Nasal Polyps Treatment with Growing Research Activities
4.3 Market Restraints
4.3.1 High Cost and Complications Associated with Sinus Surgeries
4.3.2 Adverse Reactions Associated with Steroid Therapies such as Visual Impairment, Excessive Bleeding, and Recurrence of Nasal Polyps
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Corticosteroids
5.1.2 Antibiotics
5.1.3 Leukotriene Inhibitors
5.1.4 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Nasal
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United states Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Sanofi S.A
6.1.2 OptiNose US
6.1.3 Merck & Co Inc
6.1.4 Intersect ENT Inc
6.1.5 GlaxoSmithKline PLC
6.1.6 Teva Pharmaceutical Industries
6.1.7 Regeneron Pharmaceuticals Inc
6.1.8 F. Hoffmann-La Roche AG
6.1.9 Novartis International AG
6.1.10 Norton Waterford Ltd
6.1.11 Pfizer Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Sanofi S.A
  • OptiNose US
  • Merck & Co Inc
  • Intersect ENT Inc
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals Inc
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Norton Waterford Ltd
  • Pfizer Inc.
Note: Product cover images may vary from those shown